Skip to main content
SpringerLink
Log in

The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The effects of treatment with a somatostatin analog (Sandostatin, SMS201-995) were investigated in female rats with dimethylbenzanthracene(DMBA)-induced rat mammary tumors. A 3-week treatment was performed using sandostatin, the LHRH-agonist buserelin alone, or buserelin in combination with sandostatin. Twice daily sandostatin treatment was performed with dosages of 0.05 µg, 0.2 µg, 1 µg, 5 µg, and 20 µg. Buserelin was used in a 2 × 5 µg/day dosage.

The combined results from six different experiments show that the various dosages of sandostatin caused no tumor growth inhibition. Somatostatin receptors could not be demonstrated in these mammary tumors. Sandostatin treatment by daily injections did not suppress levels of growth hormone, prolactin, or epidermal growth factor-like activities. Estrogen (ER) and progesterone (PgR) receptor contents of the mammary tumors were not changed. In contrast, buserelin treatment caused highly significant tumor remission. The combined treatment with sandostatin and buserelin did not alter the treatment results obtained after treatment with buserelin alone.

In conclusion, sandostatin treatment in this tumor model had no direct growth inhibitory effect and did not cause an endocrine inhibition of mammary tumor growth. However, these results do not exclude antitumor effects in human breast cancer in view of the presence of somatostatin receptors in approximately 20–45% of human tumors, besides possible different endocrine effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lawson DM, Sensui N, Haisenleder DH, Kaufman PN, Gala RR: Prolactin levels and molecular heterogeneity in rat strains with high and low incidence of DMBA-induced mammary tumors. Breast Cancer Res Treat 4: 129–136, 1984

    PubMed  Google Scholar 

  2. Nicholson RI, Walker KJ, Davies P: Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer. Cancer Surv 5: 463–486, 1986

    PubMed  Google Scholar 

  3. Bruning PF: Prolactin and breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)steroidal Agents. EORTC Monograph Series, Raven Press, New York, vol 18: 167–173, 1987

    Google Scholar 

  4. L'Hermite-Balériaux M, Casteels S, L'Hermite M: Prolactin receptors in breast cancer: importance of the membrane preparation: In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)steroidal Agents. EORTC Monograph Series, Raven Press, New York, vol 18: 157–165, 1987

    Google Scholar 

  5. Peyrat JP, Djiane J, Kelly PA, Vandewalle B, Bonneterre J, Demaille A: Characterization of prolactin receptors in human breast cancer. Breast Cancer Res Treat 4: 275–281, 1984

    PubMed  Google Scholar 

  6. Murphy LJ, Murphy LC, Vrhovsek E, Sutherland RL, Lazarus L: Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. Cancer Res 44: 1963–1968, 1984

    PubMed  Google Scholar 

  7. Murphy LJ, Vrhovsek E, Sutherland RL, Lazarus L: Growth hormone binding to cultured human breast cancer cells. J Clin Endocrinol Metab 58: 149–156, 1984

    PubMed  Google Scholar 

  8. Emerman JT, Leaky M, Gout PW, Bruchovsky N: Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17: 421–424, 1985

    PubMed  Google Scholar 

  9. Pierrepoint CG, Turkes AO, Walker KJ, Harper ME, Wilson DW, Peeling WB, Griffiths K: Endocrine factors in the treatment of prostatic cancer. In: Schroeder FH, Richards B (eds) Therapeutical Principles in Metastatic Prostatic Cancer, Alan R. Liss, New York, 1985, pp 51–72

    Google Scholar 

  10. Davoren JB, Hsueh AJW: Growth hormone increases ovarian levels of immunoreactive somatomedin C/insulinlike growth factor-1in vivo. Endocrinol 118: 888–890, 1986

    Google Scholar 

  11. Goustin AS, Leof EB, Shipley GD, Moses HL: Growth factors and cancer. Cancer Res 46: 1015–1029, 1986

    PubMed  Google Scholar 

  12. Schally AV, Redding TW, Cai RZ, Paz JI, Ben-David M, Comaru-Schally AM: Somatostatin analogs in the treatment of various experimental tumors. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors, and New (Anti)steroidal Agents. EORTC Monograph Series, Raven Press, New York, vol 18: 431–441, 1987

    Google Scholar 

  13. Schally AV: Oncological applications of somatostatin analogs. Cancer Res 48: 6977–6985, 1988

    PubMed  Google Scholar 

  14. Lamberts SWJ, Krenning EP, Klijn JGM, Reubi JC: The clinical use of somatostatin analogs in the treatment of cancer. Baillière's Clinical Endocrinology and Metabolism 3: 29–49, 1990

    Google Scholar 

  15. Lippman ME: Growth regulation of human breast cancer. Clin Res 83: 375–382, 1985

    Google Scholar 

  16. Pekonen F, Partanen S, Makinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor-1 and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343–1347, 1988

    PubMed  Google Scholar 

  17. Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A: Insulin-like growth factor-1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 48: 6429–6433, 1988

    PubMed  Google Scholar 

  18. Foekens JA, Portengen H, Janssen M, Klijn JGM: Insulin-like growth factor-1 (IGF-1) receptors and IGF-1-like activity in human primary breast cancer. Cancer 63: 2139–2147, 1989

    PubMed  Google Scholar 

  19. Foekens JA, Portengen H, Van Putten WLJ, Trapman AMAC, Reubi JC, Alexieva-Figusch J, Klijn JGM: The prognostic value of receptors for insulin-like growth factor-1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49: 7002–7009, 1989

    PubMed  Google Scholar 

  20. Klijn JGM, Portengen H, Van Putten WLJ, Trapman AMAC, Reubi JC, Alexieva-Figusch J, Foekens JA: The prognostic value of receptors for somatostatin, insulin-like growth factor (IGF-1) and epidermal growth factor (EGF) in human breast cancer. In: Proceedings of the 25th Annual Meeting of the American Society of Clinical Oncology, p21, abstract 78, 1989

  21. Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM: Direct inhibitory effects of somatostatin (analogs) on the growth of human breast cancer cells. Cancer Res 47: 1566–1570, 1987

    PubMed  Google Scholar 

  22. Klijn JGM, Setyono-Han B, Bakker GH, Henkelman MS, Portengen H, Foekens JA: Effects of somatostatin analog (sandostatin) treatment in experimental and human cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)steroidal Agents. EORTC Monograph Series, Raven Press, New York, vol 18: 459–468, 1987

    Google Scholar 

  23. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JGM: Endocrine and antitumor effects of combined treatment with an antiprogestin and an antiestrogen or an LHRH-agonist in female rats bearing mammary tumors. Endocrinol 125: 1593–1598, 1989

    Google Scholar 

  24. Lamberts SWJ, Reubi JC, Uitterlinden P, Zuiderwijk J, Van den Werff P, Van Hal P: Studies on the mechanism of action of the inhibitory effect of somatostatin analog SMS201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinol 118: 2188–2194, 1986

    Google Scholar 

  25. Blankenstein MA, Peters-Mechielsen MJ, Mulder E, Van der Molen HJ: Estimation of the total estrogen receptors in DMBA-induced rat mammary tumors by exchange of nuclear bound ligand at low temperature: a comparison with rat uterus. J Steroid Biochem 13: 557–564, 1980

    PubMed  Google Scholar 

  26. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1515, 1980

    Google Scholar 

  27. Reubi JC, Heitz PU, Landolt AM: Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 65: 65–73, 1987

    PubMed  Google Scholar 

  28. Reubi JC, Haecki WH, Lamberts SWJ: Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65: 1127–1134, 1987

    PubMed  Google Scholar 

  29. Reubi JC, Probst A, Cortes R, Palacios JM: Distinct topographical localization of two somatostatin receptor subpopulations in the human cortex. Brain Res 406: 391–396, 1987

    PubMed  Google Scholar 

  30. Welschen R, Osman P, Dullaart J, De Greef WJ, Uilenbroek JThJ, De Jong FH: Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17β and progesterone, and follicular growth in the pseudopregnant rat. J Endocrinol 64: 37–47, 1975

    PubMed  Google Scholar 

  31. Millar RP, Klaff LJ, Barron J, Levitt NS, Luig N: Somatostatin-28 inhibits LHRH-stimulated gonadotropin secretion in man. Clin Endocrinol 17: 103–107, 1982

    Google Scholar 

  32. Chiodera P, Volpi R, d'Amato L, Fatone M, Cigarini C, Fava A, Caiazza A, Rossi G, Covio V: Inhibition by somatostatin of LHRH-induced LH release in normal menstruating women. Gynecol Obstet Invest 22: 17–21, 1986

    PubMed  Google Scholar 

  33. Schally AV, Redding TW: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 84: 7275–7279, 1987

    PubMed  Google Scholar 

  34. Rose DP, Gottardis M, Noonan JJ: Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin. Anticancer Res 3: 323–326, 1983

    PubMed  Google Scholar 

  35. Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV: Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of luteinizing hormone-releasing hormone and somatostatin. Breast Cancer Res Treat 14: 307–314, 1989

    PubMed  Google Scholar 

  36. Liebow C, Reilly C, Serrano M, Schally AV: Somatostain analogs inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86: 2003–2007, 1989

    PubMed  Google Scholar 

  37. Klijn JGM, Setyono-Han B, Bakker GH, Foekens JA: Dose-effect finding studies on endocrine parameters and tumor growth by the somatostatin analog RC-160 in rat pancreatic tumors. Program and abstracts of the Sixth NCIEORTC Symposium on new Drugs in Cancer Therapy, Amsterdam, abstract 241, 1989

  38. Bokser L, Schally AV: Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor-(1-29)-NH2 and decreases elevated prolactin levels in rats. Endocrinol 123: 1735–1739, 1988

    Google Scholar 

  39. Reubi JC, Maurer R, Van Werder K, Torhorst J, Klijn JGM, Lamberts SWJ: Somatostatin receptors in human endocrine tumors. Cancer Res 47: 551–558, 1987

    PubMed  Google Scholar 

  40. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J: Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EJF receptors. Int J Cancer 46: 416–420, 1990

    PubMed  Google Scholar 

  41. Papotti M, Maci L, Bussolati G, Reubi JC: Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer 43: 365–370, 1989

    PubMed  Google Scholar 

  42. Fekete M, Wittliff JL, Schally AV: Characteristics and distribution of receptors for [D-Trp6]-luteinizing hormonereleasing hormone, somatostatin, epidermal growthfactor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137–141, 1989

    PubMed  Google Scholar 

  43. Weber C, Merriam L, Koschitzky T, Karp F, Benson M, Forde K, LoGerfo P: Inhibition of growth of human breast carcinomasin vivo by somatostatin analog SMS 201–995: treatment of nude mouse xenografts. Surgery 106: 416–422, 1989

    PubMed  Google Scholar 

  44. Manni A, Boucher AE, Harvey H, Lipton A, Simmonds M: Combined somatostatin analog and bromocriptine therapy in the treatment of advanced breast cancer. Program and abstracts, The Endocrine Society, New Orleans, abstract 1328, 1988, p 352

    Google Scholar 

  45. Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14: 289–298, 1989

    PubMed  Google Scholar 

  46. Vennin PH, Peyrat JP, Bonneterre J, Louchez MM, Harris AG, Demaille A: Effect of the long-acting somatostatin analog SMS201-995 (sandostatin) in advanced breast cancer. Anticancer Res 9: 153–156, 1989

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Statistics, The Dr. Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands

    W. L. J. van Putten

  2. Department of Biochemistry (Chemical Endocrinology), Erasmus University, Rotterdam, The Netherlands

    F. H. de Jong

  3. Department of Internal Medicine, Erasmus University, Rotterdam, The Netherlands

    S. W. J. Lamberts

  4. Sandoz Research Institute, Bern, Switzerland

    J. C. Reubi

  5. Division of Endocrine Oncology (Biochemistry and Endocrinology), The Dr Daniel Den Hoed Cancer Center, P.O. Box 5201, 3008 AE, Rotterdam, The Netherlands

    G. H. Bakker, B. Setyono-Han, J. A. Foekens, H. Portengen, W. L. J. van Putten, F. H. de Jong, S. W. J. Lamberts, J. C. Reubi & J. G. M. Klijn

Authors
  1. G. H. Bakker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Setyono-Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. A. Foekens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Portengen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. L. J. van Putten
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. H. de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. W. J. Lamberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. C. Reubi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. G. M. Klijn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bakker, G.H., Setyono-Han, B., Foekens, J.A. et al. The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors. Breast Cancer Res Tr 17, 23–32 (1990). https://doi.org/10.1007/BF01812681

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01812681

Key words

Search

Navigation